Cyprotex receives dual boost for research development
Cyprotex PLC, a drug discovery technology and information company, announced it has received peer-approved publication of its "virtual human and rat" system, known as Cloe PK(R). The details of extensive validation results for Cloe PK(R) showing how the technology can estimate blood levels of new drugs without the use of animals, have been accepted for publication by "Drug metabolism and Disposition", a prestigious peer-reviewed journal encompassing work in this scientific area.
Cyprotex has also been awarded a grant by The Department of Trade & Industry (DTI) to extend the group's predictive technologies used in the invention of new drugs. This news follows a recent announcement that Cyprotex is forming its own research group, Cyprotex Research Ltd, which will be aimed at eradicating drug liabilities from the very earliest stages of drug discovery. The research group, which will be headed by Dr David Leahy, Cyprotex's Founder and Chief Technical Officer, will form academic and industrial collaborations to develop computational capabilities, to facilitate R&D productivity improvements throughout the industry. New tools and capabilities developed via the research group will be commercialised and offered to Cyprotex's pharmaceutical and biotechnology partners.
Other news from the department research and development
